WATSON Laboratories has
received US Food and Drug
Administration approval for its
diclofenac sodium and misoprostol
delayed-release tablets, the generic
equivalent to G.D. Searle's
Arthrotec.
The tablets are indicated for the
treatment of the signs and
symptoms of osteoarthritis or
rheumatoid arthritis in patients at
high risk of developing NSAIDinduced
gastric and duodenal
ulcers and their complications.
Watson now plans to launch the
product in the fourth quarter of
2012.
See www.fda.gov for details.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Jul 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Jul 12
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FROM 01 May, pharmacists will be able to dispense Verzenio (abemaciclib) through the PBS to treat Australian patients with an invasive form of early breast cancer that is at high risk of recurring after initial treatment.
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.